Novo Nordisk, a Danish pharma group, has named Pinder Sahota as its new general manager and corporate vice president, UK, it was reported yesterday.
Sahota, who brings experience from business, commercial and leadership roles to Novo, was most recently responsible for creating commercial and market development strategies across Europe as senior vice president of market and commercial development for Europe at Smith & Nephew.
He began his pharmaceutical career in sales and marketing with companies that formed Sanofi Aventis, then moved to SmithKline Beecham, now GlaxoSmithKline, where he held a number of commercial leadership roles including vice president of commercial operations of diabetes and cardiovascular. In 2009 Sahota moved to AstraZeneca to take up the role of vice president for primary care in the UK, and was in that position until moving to the role of managing director for the UK and Ireland for Smith & Nephew in 2013.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business